Recordati closed 2012 with a net profit up by 1,8% (equal to 118,5 million). The board of directors of the European pharmaceutical group has approved the 2012 financial statements. The board of directors will propose to the shareholders' meeting the distribution of a dividend of 0,3 euros (i.e. 0,1 as the balance of the 2012 interim payment of 0,2 EUR).
Consolidated revenues grew by 8,7% (828,3 million) and operating profit by 167,0 million (+2,1%). Pharmaceutical sales amounted to 797,4 million (+8,7%) and sales of pharmaceutical chemicals to 30,9 million (+8,9%). Net financial debt, which as at 31 December 2011 was equal to 55,7 million, in 2012 stood at around 153,5 million.
Sales in the first few months of 2013 seem to confirm Recordati's expectations for the entire year. The group expects to achieve revenues of more than 920 million, an operating profit of more than 185 million and a net profit of more than 128 million.
